高级搜索

子宫颈鳞状细胞癌组织中LncRNA HCG11和miR-590-3p的表达及其与预后的关系

陈晓杰, 刘平

陈晓杰, 刘平. 子宫颈鳞状细胞癌组织中LncRNA HCG11和miR-590-3p的表达及其与预后的关系[J]. 肿瘤防治研究, 2018, 45(3): 148-153. DOI: 10.3971/j.issn.1000-8578.2018.17.0614
引用本文: 陈晓杰, 刘平. 子宫颈鳞状细胞癌组织中LncRNA HCG11和miR-590-3p的表达及其与预后的关系[J]. 肿瘤防治研究, 2018, 45(3): 148-153. DOI: 10.3971/j.issn.1000-8578.2018.17.0614
CHEN Xiaojie, LIU Ping. Expression of LncRNA HCG11 and miR-590-3p in Squamous Carcinoma of Cervix and Their Relationship with Prognosis[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 148-153. DOI: 10.3971/j.issn.1000-8578.2018.17.0614
Citation: CHEN Xiaojie, LIU Ping. Expression of LncRNA HCG11 and miR-590-3p in Squamous Carcinoma of Cervix and Their Relationship with Prognosis[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 148-153. DOI: 10.3971/j.issn.1000-8578.2018.17.0614

子宫颈鳞状细胞癌组织中LncRNA HCG11和miR-590-3p的表达及其与预后的关系

详细信息
    作者简介:

    陈晓杰(1981-),女,博士,讲师,主要从事肿瘤表观遗传学的研究

    通讯作者:

    刘平,E-mail: m18538827625@163.com

  • 中图分类号: R737.33

Expression of LncRNA HCG11 and miR-590-3p in Squamous Carcinoma of Cervix and Their Relationship with Prognosis

More Information
  • 摘要:
    目的 

    探讨LncRNA HCG11和miR-590-3p在子宫颈鳞状细胞癌组织及配对的癌旁组织中的表达情况,以及二者表达水平与患者临床资料和预后的相关性。

    方法 

    收集58例子宫颈鳞状细胞癌和配对的癌旁正常组织标本,运用qRT-PCR法检测58对子宫颈鳞状细胞癌组织及相应的癌旁组织中的LncRNA HCG11和miR-590-3p的表达,分析与宫颈鳞状细胞癌临床病理和预后的相关性,并评价其临床意义。

    结果 

    荧光定量PCR显示宫颈鳞状细胞癌组织中LncRNA HCG11的表达比癌旁组织明显下调(P < 0.05),miR-590-3p的表达比癌旁组织明显上调(P < 0.05);二者在核酸表达水平上呈负相关(r=-0.642, P=0.000)。LncRNA HCG11和miR-590-3p的表达均与宫颈癌淋巴结转移、组织大小及临床分期之间存在显著的相关性,且与预后相关(P < 0.05)。Cox回归多因素分析发现LncRNA HCG11和miR-590-3p分别可作为宫颈鳞状细胞癌患者独立的预后因子。

    结论 

    LncRNA HCG11和miR-590-3p可作为宫颈鳞状细胞癌独立的预后标志物和潜在的治疗靶点,LncRNA HCG11可能通过调控miR-590-3p的表达量从而发挥抑癌基因的作用。

     

    Abstract:
    Objective 

    To investigate the expression of long non-coding RNA (LncRNA) HCG11 and miR-590-3p in squamous carcinoma of cervix and paired adjacent tissues, and their correlation with patients' clinical data and prognosis.

    Methods 

    Specimens of cervical cancer tissues and matched non-tumor para-neoplastic tissues were collected from 58 patients who underwent surgery in The Second People's Hospital of Nanyang. Quantitative real-time PCR was used to examine the expression of LncRNA HCG11 and miR-590-3p, the correlation between them was be analyzed, and we also analyzed their correlation with clinicopathological features and prognosis.

    Results 

    LncRNA HCG11 expression was significantly down-regulated in squamous carcinoma of cervix tissues as compared with adjacent non-tumor tissues(P < 0.05); the expression of miR-590-3p was significantly up-regulated in squamous carcinoma of cervix tissues as compared with the adjacent non-tumor tissues(P < 0.05); their expression levels of nucleic acid showed a negative correlation (r=0.642, P=0.000). LncRNA HCG11 and miR-590-3p expression were significantly correlated with FIGO stage, lymph node metastasis, tissue size of tumor and prognosis(P < 0.05). Multivariate analysis suggested that LncRNA HCG11 or miR-590-3p expression served as independent predictors for overall survival respectively.

    Conclusion 

    LncRNA HCG11 and miR-590-3p may be potential prognostic markers and therapeutic targets for squamous carcinoma of cervix. LncRNA HCG11 may play the role of tumor suppressor by means of regulating the expression of miR-590-3p.

     

  • 肝癌是全球常见的恶性肿瘤之一,病理类型有肝细胞癌(hepatocellular carcinoma, HCC)、肝内胆管细胞癌、混合癌,其中肝细胞癌占85%~90%[1]。根据2020年癌症全球人数统计,肝癌是全球第三大癌症死亡原因,死亡人数占癌症总死亡人数的8.3%,是中国癌症死亡人数的第2名[2]。我国肝癌5年生存率不足15%[3]。甲胎蛋白(alpha-fetoprotein, AFP)是筛查HCC的常用指标,术后AFP升高常提示HCC复发,但约30%的患者AFP没有升高或不表达,延误治疗最佳时机[4]。临床上需要联合有效的指标协助判断患者预后,提高生存质量。

    血清乳酸脱氢酶/白蛋白比值(lactate dehydrogenase to albumin ratio, LAR)是判断恶性肿瘤预后的血清学检测指标之一。在多种癌症的研究中显示,血清乳酸脱氢酶(LDH)水平是肿瘤缺氧、新生血管生成和预后不良的间接标志[5]。术前低蛋白血症是营养不良的指标,与胃癌和肝癌等患者的总体存活率低和复发率高有关[5-6]。LAR在胃癌和鼻咽癌等癌症中的不良预后作用已被验证,而在HCC中研究较少。本研究回顾性分析106例HCC患者临床资料,评价患者术前外周血LAR与预后的关系,并将LAR联合AFP来评估HCC患者预后的价值,以期为HCC的临床判断提供一定的参考。

    回顾性分析2015年1月—2019年12月在兰州大学第一医院普外科行根治性手术的106例HCC患者的临床资料,其中男81例(76.4%),女25例(23.6%);年龄26~78(54.5±10.1)岁。临床分期按照2018年修改的AJCC第8版分期系统。纳入标准:(1)18~80岁;(2)术中肿瘤根治性切除;(3)术后病理证实为HCC;(4)无严重的心、肺、脑、肾严重功能障碍及血液系统疾病;(5)患者临床及随访资料完整。排除标准:(1)不可切除或非根治性切除的肝癌;(2)术后病理证实非HCC;(3)既往有其他恶性肿瘤病史者;(4)拒绝签署知情同意书及随访过程中失访者。本研究通过本院伦理委员会审批(批准号:LDYYLL2021-348)。

    收集患者的基本信息:性别、年龄、体重指数;术前1周内的血常规检查:肝炎病毒抗原、白蛋白(ALB)、LDH、AFP;影像学检查;疾病信息:肿瘤T分期、N分期、临床分期、术后有无介入手术治疗等。

    采用住院或门诊就诊、电话等方式进行随访,每3月随访一次,末次随访时间为2021年5月。总生存期(overall survival, OS)是从患者术后第1日开始至末次随访或死亡的时间;无病生存期(disease-free survival, DFS)是患者手术后第1日至疾病复发或(因任何原因)死亡之间的时间[7]。随访时间为0~77月,中位随访时间为28月。106例随访病例复发75例(70.8%),死亡30例(28.3%),1例未复发。

    采用SPSS26.0软件进行统计学分析。根据中位数以LAR为4.58进行分层(LAR≥4.58和LAR < 4.58)。计数资料用例数和百分比表示,两组间比较采用χ2或Fisher精确检验,等级变量采用秩和检验。使用Kaplan-Meier绘制生存曲线并采用Log rank检验。利用Cox风险回归模型进行单多因素回归分析,判断影响HCC患者预后的危险因素;对LAR和AFP联合分组进行检验,并绘制Kaplan-Meier生存曲线。P < 0.05为差异有统计学意义。

    106例患者中,1年的DFS为49.1%,3年的DFS为9.4%,1年的OS为81.1%,3年的OS为22.6%。根据既往研究结果,取AFP截断值为400 μg/L,以LAR=4.58为阈值分层,单因素分析显示两组间T分期和临床分期比较差异有统计学意义(均P < 0.05),见表 1

    表  1  HCC患者的临床资料与LAR相关性分析(n(%))
    Table  1  Correlation between clinical data and LAR of HCC patients (n(%))
    下载: 导出CSV 
    | 显示表格

    高LAR组(LAR≥4.58, n=53),低LAR组(LAR < 4.58, n=53);高AFP组(AFP≥400 μg/L, n=24),低AFP组(AFP < 400 μg/L, n=82)。Log rank检验单因素分析显示,高LAR组和高AFP组的DFS和OS显著短于低LAR组和低AFP组,差异有统计学意义(P < 0.05),Kaplan-Meier生存曲线见图 1

    图  1  不同的LAR和AFP值与HCC患者术后无病生存期(A, C)和总生存期(B, D)的关系
    Figure  1  Relation between different LAR, AFP values and postoperative DFS(A, C), OS(B, D) of HCC patients

    按照中位数患者被分为高LAR组(LAR≥4.58, n=53)和低LAR组(LAR < 4.58, n=53)。根据既往文献对T分期进行分类(T1~T2/T3~T4),将HCC患者性别、年龄、BMI、肝炎病毒抗原、LAR、AFP、T分期、N分期和术后介入治疗等因素纳入Cox单因素回归分析,结果表明LAR、AFP、T分期与DFS相关(P < 0.05),LAR、AFP、T分期、术后介入治疗与OS相关(P < 0.05)。将单因素分析中有临床意义的变量纳入多因素回归分析,结果显示高LAR、高AFP和T3~T4期是HCC患者DFS和OS的独立危险因素(P < 0.05),术后行介入手术治疗可延长HCC患者的OS,见表 2

    表  2  HCC患者DFS和OS的Cox单多因素回归分析
    Table  2  Cox univariate and multivariate regression analyses of DFS and OS in HCC patients
    下载: 导出CSV 
    | 显示表格

    结果显示高LAR且高AFP组(LAR≥4.58且AFP≥400 μg/L, n=12)的DFS和OS最短,低LAR且低AFP组(LAR < 4.58且AFP < 400 μg/L, n=41)的DFS和OS最长(P < 0.05),见图 2

    图  2  血清LAR及AFP水平与肝细胞患者术后无病生存期(A)和总生存期(B)的关系
    Figure  2  Relation between serum LAR, AFP levels and postoperative DFS(A), OS(B) of HCC patients

    肝癌是我国第四大常见恶性肿瘤[8],据2018年世界卫生组织(WHO)统计,我国肝癌人数占全球肝癌病例总数的46.7%[9]。肝癌主要的危险因素有慢性乙型病毒性肝炎、慢性丙型病毒性肝炎、酗酒、代谢性肝病等。目前AFP作为临床最常用的血液学检测方法对HCC进行筛查和预后监测,但其敏感度较低,为25%~65%[1]。因此需联合简单可行的血液学检测方法对HCC预后进行判断,早期实施干预措施,改善HCC预后。

    高LDH和低ALB水平提示恶性肿瘤的不良预后,LAR将LDH与ALB结合可在肿瘤血管生成、细胞存活和机体营养状况等方面综合判断肿瘤预后,准确性较单个指标更高,其不良预后作用在结直肠癌、食管癌等多种肿瘤中得到验证[10-11]。Gan等[6]对1 041例原发性肝癌患者进行分析,发现LAR是原发性肝癌患者OS和无进展生存期(progression-free survival, PFS)的准确预测因子。本研究发现术前LAR与肿瘤的T分期和临床分期相关,与以往研究结果一致,高LAR是HCC的独立不良预后因素,高LAR水平的HCC患者,术后复发风险比低LAR组高约1.606倍。

    LDH是一种参与无氧糖酵解的代谢酶[11],高LDH与肿瘤血管生成、细胞存活和肿瘤形成相关[12],是胃癌、胰腺癌等恶性肿瘤的不良预后因素[10-11, 13]。Wu等[14]研究显示LDH是原发性肝癌患者OS和PFS的独立预后因素。高LDH提示不良预后的可能原因有:(1)肿瘤细胞增殖活跃、肿瘤微环境氧耗增加[15]、缺氧诱导因子-1(HIF-1)的异常激活可上调肿瘤细胞中的LDH-A,确保肿瘤细胞在低氧条件下进行糖酵解代谢并且减少对氧气的需求[16];(2)PI3K/Akt/mTOR通路是肿瘤中最常被激活的信号通路之一,可通过调节LDH促进肿瘤细胞增殖、生长[17];(3)异常激活的热休克蛋白通过其转录调节因子热休克因子(HSF-1),调节葡萄糖代谢和增加乳酸脱氢酶(LDH-A)的表达[18],促进肿瘤细胞的增值、侵袭和转移。ALB作为肝脏合成的糖蛋白,是判断肝功能是否损伤的早期重要指标[19]。Fox等[20]通过分析2 918例患者的临床资料发现术前低蛋白血症为原发性肝癌不良预后的重要因素。术前白蛋白水平较低的原因可能有:肝功能障碍引起白蛋白合成、分泌较少;肿瘤相关的炎性反应引起蛋白分解加速[5]。LAR为LDH和ALB值之比,LAR升高不仅可以反应LDH升高,也可反应ALB降低。本研究通过对106例患者分析发现高LAR组患者的DFS和OS短于低LAR组患者,且差异有统计学意义(P < 0.05),与上述研究结果基本一致。

    本研究发现,LAR和AFP均与HCC的不良预后密切相关,LAR和AFP均升高的组预后最差,对HCC患者术后DFS和OS的判断有统计学意义。本研究为单中心、小样本的回顾性研究,存在一定的局限性,未来需进行多中心、大样本的前瞻性研究,进一步了解影响肝癌预后的危险因素,提高对肝癌预后判断的准确性,及时干预治疗,延长DFS和OS,提高患者生存质量。

  • 图  1   58对配对的宫颈鳞状细胞癌组织及癌旁组织中LncRNA HCG11和miR-590-3p的表达

    Figure  1   LncRNA HCG11 and miR-590-3p expression in 58 pairs of squamous carcinoma of cervix and adjacent non-tumor tissues

    图  2   LncRNA HCG11和miR-590-3p表达相关性分析

    Figure  2   Correlation analysis between LncRNA HCG11 and miR-590-3p expression

    图  3   LncRNA HCG11和miR-590-3p与患者的预后的关系

    Figure  3   Relationship of LncRNA HCG11 and miR-590-3p expression with patients' prognosis

    表  1   LncRNA HCG11和miR-590-3p的相对表达情况与患者临床病理因素的关系

    Table  1   Relative expression of LncRNA HCG11 and miR-590-3p and their correlation with patients' clinicopathological factors

    下载: 导出CSV

    表  2   58例宫颈鳞状细胞癌患者不同预后因素对OS的单因素和多因素分析

    Table  2   Univariate and multivariate analyses of different prognostic factors for OS of 58 patients with squamous carcinoma of cervix

    下载: 导出CSV
  • [1]

    Park JW, Bae JW. Prognostic significance of positive lymph node number in early cervical cancer[J]. Mol Clin Oncol, 2016, 4(6): 1052-6. doi: 10.3892/mco.2016.837

    [2]

    Diver E, Hinchcliff E, Gockley A, et al. Minimally Invasive Radical Hysterectomy for Cervical Cancer Is Associated With Reduced Morbidity and Similar Survival Outcomes Compared With Laparotomy[J]. J Minim Invasive Gynecol, 2017, 24(3): 402-6. doi: 10.1016/j.jmig.2016.12.005

    [3]

    Fujii T, Shimada K, Asano A, et al. MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2[J]. Int J Mol Sci, 2016, 17(8): pii: E1351. doi: 10.3390/ijms17081351

    [4]

    Etheridge A, Lee I, Hood L, et al. Extracellular microRNA: a new source of biomarkers[J]. Mutat Res, 2011, 717(1-2): 85-90. doi: 10.1016/j.mrfmmm.2011.03.004

    [5]

    Xin F, Liu P, Ma CF. Acirculating serum miRNA panel as early detection biomarkers of cervical intraepithelial neoplasia[J]. Eur Rev Med Pharmacol Sci, 2016, 20(23): 4846-51. http://www.ncbi.nlm.nih.gov/pubmed/27981553

    [6]

    Deng K, Wang H, Guo X, et al. The cross talk between long, non-coding RNAs and microRNAs in gastric cancer[J]. Acta Biochimica et Biophysica Sinica, 2016, 48(2): 111-6. doi: 10.1093/abbs/gmv120

    [7]

    Ling H. Non-coding RNAs: Therapeutic Strategies and Delivery Systems[J]. Adv Exp Med Biol, 2016, 937: 229-37. doi: 10.1007/978-3-319-42059-2

    [8]

    Colombo N, Carinelli S, Colombo A, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, Suppl 7: vii27-32. https://academic.oup.com/annonc/article/28/suppl_4/iv72/3958154/Cervical-cancer-ESMO-Clinical-Practice-Guidelines

    [9]

    Yang J, Zhang Z, Guo W, et al. Single nucleotide polymorphisms in microRNA genes are associated with cervical cancer susceptibility in a population from Xinjiang Uygur[J]. Oncotarget, 2016, 7(44): 71447-54. http://www.ncbi.nlm.nih.gov/pubmed/27677077

    [10]

    Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future[J]. Genetics, 2013, 193(3): 651-69. doi: 10.1534/genetics.112.146704

    [11]

    Xie C, Yuan J, Li H, et al. NONCODEv4: exploring the world of long non-coding RNA genes[J]. Nucleic Acids Res, 2014, 42(Database issue): D98-103. https://academic.oup.com/nar/article/42/D1/D98/1062327/NONCODEv4-exploring-the-world-of-long-non-coding

    [12]

    Volders PJ, Verheggen K, Menschaert G, et al. An update on LNCipedia: a database for annotated human lncRNA sequences[J]. Nucleic Acids Res, 2015, 43(8): 4363-4. doi: 10.1093/nar/gkv295

    [13]

    Sugihara H, Ishimoto T, Miyake K, et al. Noncoding RNA Expression Aberration Is Associated with Cancer Progression and Is a Potential Biomarker in Esophageal Squamous Cell Carcinoma[J]. Int J Mol Sci, 2015, 16(11): 27824-34. doi: 10.3390/ijms161126060

    [14]

    Wu Y, Yu DD, Hu Y, et al. WITHDRAWN: The long non-coding RNA, LINC00635-001, sensitizes EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation[J]. Biochem Biophys Res Commun, 2016, pii: S0006-291X(16)30057-2. http://www.sciencedirect.com/science/article/pii/S0006291X16300572

    [15]

    Jiang CY, Gao Y, Wang XJ, et al. Long non-coding RNA lnc-MX1-1 is associated with poor clinical features and promotes cellular proliferation and invasiveness in prostate cancer[J]. Biochem Biophys Res Commun, 2016, 470(3): 721-7. doi: 10.1016/j.bbrc.2016.01.056

    [16]

    Guo L, Lu X, Zheng L, et al. Association of Long Non-Coding RNA HOTAIR Polymorphisms with Cervical Cancer Risk in a Chinese Population[J]. PLoS One, 2016, 11(7): e0160039. doi: 10.1371/journal.pone.0160039

    [17]

    Zhang Y, Wang T, Huang HQ, et al. Human MALAT-1 long non-coding RNA is overexpressed in cervical cancer metastasis and promotes cell proliferation, invasion and migration[J]. J BUON, 2015, 20(6): 1497-503. http://www.ncbi.nlm.nih.gov/pubmed/26854446

    [18]

    Iempridee T. Long non-coding RNA H19 enhances cell proliferation and anchorage-independent growth of cervical cancer cell lines[J]. Exp Biol Med (Maywood), 2017, 242(7): 183-94. doi: 10.1177/1535370216670542

    [19]

    Sun NX, Ye C, Zhao Q, et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer[J]. PLoS One, 2014, 9(7): e100340. doi: 10.1371/journal.pone.0100340

    [20]

    Zhang J, Yao T, Wang Y, et al. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21[J]. Cancer Biol Ther, 2016, 17(1): 104-13. doi: 10.1080/15384047.2015.1108496

    [21]

    Cao S, Liu W, Li F, et al. Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer[J]. Int J Clin Exp Pathol, 2014, 7(10): 6776-83. https://www.researchgate.net/publication/268451435_Decreased_expression_of_lncRNA_GAS5_predicts_a_poor_prognosis_in_cervical_cancer

    [22]

    Liao LM, Sun XY, Liu AW, et al. Low expression of long noncoding XLOC_010588 indicates a poor prognosis and promotes proliferation through upregulation of c-Myc in cervical cancer[J]. Gynecol Oncol, 2014, 133(3): 616-23. doi: 10.1016/j.ygyno.2014.03.555

    [23]

    Zhai HY, Sui MH, Yu X, et al. Overexpression of Long Non-Coding RNA TUG1 Promotes Colon Cancer Progression[J]. Med Sci Monit, 2016, 22: 3281-7. doi: 10.12659/MSM.897072

    [24]

    Lin PC, Huang HD, Chang CC, et al. Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2[J]. BMC Cancer, 2016, 16: 583. doi: 10.1186/s12885-016-2569-6

    [25] 杨红飞, 郑文宏, 赵文沟, 等. miR-590-5p和miR-590-3p参与肝细胞肝癌发展的机制[J].南方医科大学学报, 2013, 33(6): 804-11. http://www.oalib.com/paper/5146598

    Yang HF, Zheng WH, Zhao WH, et al. Roles of miR-590-5p and miR-590-3p in the development of hepatocellular carcinoma[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2013, 33(6): 804-11. http://www.oalib.com/paper/5146598

    [26]

    Sun ZQ, Shi K, Zhou QB, et al. MiR-590-3p promotes proliferation and metastasis of colorectal cancer via Hippo pathway[J]. Oncotarget, 2017, 8(35): 5806-71. http://www.ncbi.nlm.nih.gov/pubmed/28779050

  • 期刊类型引用(9)

    1. 赵建红,岑红兵,杨志勇,陈峰. FEN1调节肝细胞癌发生和预后的临床意义. 局解手术学杂志. 2024(04): 349-354 . 百度学术
    2. 田颖,王根杰,胡青竹. 乳酸脱氢酶/白蛋白对多发性骨髓瘤患者硼替佐米化疗耐药的影响. 河南医学研究. 2024(10): 1806-1809 . 百度学术
    3. 宋丽丽,马平,管玉洁,黄闪,刘炜. 急性B淋巴细胞白血病儿童乳酸脱氢酶、前白蛋白及二者比值与化疗早期疗效的相关性. 现代临床医学. 2024(05): 326-329 . 百度学术
    4. 张郴华,邓英. 血清寡糖链与甲胎蛋白联合检测在肝细胞癌诊断及其预后评估中的应用价值分析. 大医生. 2023(09): 122-125 . 百度学术
    5. 王珊,张立婷,高晓琴,周丹. 术前抗病毒治疗对HBV-DNA阴性肝细胞癌患者术后病毒再激活及肝功能的影响. 婚育与健康. 2023(06): 37-39 . 百度学术
    6. 黎灵锋,刘桂荣,谢燕芳,巫宗由. 血清谷胱甘肽还原酶在HBV相关性肝病中的应用研究. 标记免疫分析与临床. 2023(02): 304-308 . 百度学术
    7. 汪祥兵,朱正春. LAR对信迪利单抗联合贝伐珠单抗治疗中晚期肝细胞癌患者预后的价值. 安徽医学. 2023(09): 1095-1100 . 百度学术
    8. 汪敏行,阴鲁鑫,石叶,陈洪福,褚夫政,高文昌. 脑胶质瘤患者血清MBP、LAR、AGR与术后脑损伤和预后的关系研究. 现代生物医学进展. 2023(20): 3974-3978 . 百度学术
    9. 仲伟明,吴银亚,段后张,刘雷,蔡景治. 血清ESM-1水平预测肝细胞癌患者射频消融术后早期复发的临床意义. 临床肿瘤学杂志. 2023(10): 907-912 . 百度学术

    其他类型引用(3)

图(3)  /  表(2)
计量
  • 文章访问数:  1205
  • HTML全文浏览量:  345
  • PDF下载量:  306
  • 被引次数: 12
出版历程
  • 收稿日期:  2017-06-04
  • 修回日期:  2017-09-19
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2018-03-24

目录

/

返回文章
返回
x 关闭 永久关闭